B
Bull
Bull · 25%PACB
$1.08
情境價格
$1.400
-0.136 (-9.68%)收盤時
Loading chart…
- High
- 1.545
- Open
- 1.520
- VWAP
- 1.44
- Vol
- 5.23M
- Mkt Cap
- 370.40M
- Low
- 1.390
- Amount
- 7.56M
- EV/EBITDA, TTM
- -5.97
Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. It focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.
AI analysis of Pacific Biosciences of California Inc (PACB)
holdPacific Biosciences (PACB) is currently not a strong buy due to its recent performance and outlook. The stock is priced at $1.40, which is below the analyst target of $1.50, indicating limited upside potential. Additionally, the company reported a significant year-to-date decline of 23.91% and has a negative forward P/E ratio of 0, reflecting uncertainty in future earnings. The recent resignation of the CEO and a downgraded revenue outlook for 2026 to $155-$165 million further complicate the investment case. The main risk lies in the company's high debt-to-equity ratio of 27223.46%, which poses a financial stability concern. Overall, while there are some positive indicators, such as a recent 5-day price increase of 3.70%, the overall sentiment and financial metrics suggest holding rather than buying at this time.
Analyst Ratings (6)
+71.43% upside
Hold
2 Buy
4 Hold
0 Sell
Current: 1.40
最低
2.00
平均
2.40
最高
3.00
Barclays
Underweight
$1
2026-05-11
Barclays
2026-05-11
目標價
$1
Underweight
Barclays
Underweight
$1
2026-04-14
Barclays
2026-04-14
目標價
$1
Underweight
Barclays
Underweight
$1.50
2026-03-06
Barclays
2026-03-06
目標價
$1.50
Underweight
Barclays
Equal Weight
$2
2025-12-15
Barclays
2025-12-15
目標價
$2
Equal Weight
Piper Sandler
Neutral
$2
2025-11-11
Piper Sandler
2025-11-11
目標價
$2
Neutral
估值指標
The current forward P/E ratio for Pacific Biosciences of California Inc (PACB) is 0.00, compared to its 5-year average forward P/E of -6.44.
Alphio AI Price Scenarios for PACB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding PACB
事件時間軸
資訊
9.508-06seekingalphaPacific Biosciences Q2 2026 Earnings Call Insights
5.008-05NewsfilterPacBio Unveils Vega SPRQ-Nx Chemistry Enhancements
6.507-03Yahoo FinanceRisk Analysis of Three Wall Street Favorites
- 8.505-26Newsfilter
PacBio Launches Next-Gen Sequencing Technology with SPRQ-Nx
- 7.505-19Newsfilter
Blank Bio Collaborates with PacBio to Advance Tumor Transcriptome Research
PACB FAQ — answered by Alphio AI
Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. It focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Pacific Biosciences (PACB) is currently not a strong buy due to its recent performance and outlook. The stock is priced at $1.40, which is below the analyst target of $1.50, indicating limited upside potential. Additionally, the company reported a significant year-to-date decline of 23.91% and has a negative forward P/E ratio of 0, reflecting uncertainty in future earnings. The recent resignation of the CEO and a downgraded revenue outlook for 2026 to $155-$165 million further complicate the investment case. The main risk lies in the company's high debt-to-equity ratio of 27223.46%, which poses a financial stability concern. Overall, while there are some positive indicators, such as a recent 5-day price increase of 3.70%, the overall sentiment and financial metrics suggest holding rather than buying at this time.
6 analysts cover PACB: 2 rate it Buy, 4 Hold and 0 Sell. The average price target is 2.40.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。